Form 4: Cognition Therapeutics Director and Related Entities Acquire Shares and Options

Leslie W. Kreis, along with associated entities, reports the acquisition of shares and options in Cognition Therapeutics, Inc. related to restricted stock units.

Summary

• Leslie W. Kreis, a director of Cognition Therapeutics Inc. (CGTX), along with several related entities, filed a Form 4 disclosing changes in beneficial ownership.
• The reported transactions include the acquisition of 8,500 shares represented by restricted stock units (RSUs) and an option to buy 8,500 shares at $1.95.
• The RSUs and options vest on the earlier of June 7, 2025, or the date of the Issuer's next annual meeting of stockholders, subject to Dr. Fletcher's continuous service as a director.
• The filing also details indirect beneficial ownership of common stock held by various Bios Equity Partners funds.
• The total indirect holdings across these funds amount to several million shares.
• This Form 4 is one of two filings related to the same event, with the other filed by Mr. Fletcher due to SEC limitations on the number of reporting persons per form.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The acquisition of shares and options by a director is generally viewed as a positive sign, but the filing primarily reflects required disclosures.

Positives

• The acquisition of shares and options by a director could be interpreted as a positive signal regarding the company's future prospects.

Industry Context

Form 4 filings are standard disclosures required by the SEC to provide transparency regarding insider transactions. These filings are closely watched by investors to gauge the sentiment of company insiders.

Stakeholder Impact

• The reported transactions may influence investor perception of Cognition Therapeutics.

Key Dates